樂觀
$210.76
情境價格
$154.510
-0.989 (-0.64%)收盤時
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
Align Technology Inc is currently a hold. The stock is trading at $154.51, which is significantly below the estimated intrinsic value of $311 per share, indicating potential undervaluation. However, the stock has a high RSI of 74.36, suggesting it may be overbought in the short term. Additionally, the forward P/E ratio is 11.67, which is attractive compared to its current P/E of 57.39, but the recent downgrades from analysts, including a target reduction to $155 from $220 by Evercore ISI, raise concerns about future growth. The main risk is the declining consumer sentiment reflected in the recent retail sales data, which fell by 0.6% month-over-month, potentially impacting Align's sales.
Stifel
$175
2026-10-09
Stifel
2026-10-09
目標價
$175
Evercore ISI
$155
2026-10-05
Evercore ISI
2026-10-05
目標價
$155
UBS
$189
2026-07-23
UBS
2026-07-23
目標價
$189
BMO Capital
$209
2026-07-08
BMO Capital
2026-07-08
目標價
$209
Leerink
$230
2026-06-30
Leerink
2026-06-30
目標價
$230
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Major Risks Loom for Stock Market Next Week Amid AI Trade Stumbles

Align Technology Wins Patent Infringement Case Against Angelalign

Align Technology to Report Q3 2026 Financial Results

Align Technology Stock Performance Analysis

Weak US Retail Sales Impact Markets
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Align Technology Inc is currently a hold. The stock is trading at $154.51, which is significantly below the estimated intrinsic value of $311 per share, indicating potential undervaluation. However, the stock has a high RSI of 74.36, suggesting it may be overbought in the short term. Additionally, the forward P/E ratio is 11.67, which is attractive compared to its current P/E of 57.39, but the recent downgrades from analysts, including a target reduction to $155 from $220 by Evercore ISI, raise concerns about future growth. The main risk is the declining consumer sentiment reflected in the recent retail sales data, which fell by 0.6% month-over-month, potentially impacting Align's sales.
11 analysts cover ALGN: 11 rate it Buy, 0 Hold and 0 Sell. The average price target is 198.70.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。